$210,000.00 in Sales Expected for Compugen Ltd. (CGEN) This Quarter
Analysts forecast that Compugen Ltd. (NASDAQ:CGEN) will report sales of $210,000.00 for the current quarter, according to Zacks. Two analysts have provided estimates for Compugen’s earnings, with estimates ranging from $20,000.00 to $400,000.00. Compugen posted sales of $500,000.00 during the same quarter last year, which would indicate a negative year-over-year growth rate of 58%. The business is scheduled to issue its next earnings results on Tuesday, August 1st.
According to Zacks, analysts expect that Compugen will report full-year sales of $210,000.00 for the current fiscal year, with estimates ranging from $70,000.00 to $6.50 million. For the next financial year, analysts expect that the business will report sales of $24.04 million per share, with estimates ranging from $8.00 million to $40.07 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Compugen.
Compugen (NASDAQ:CGEN) last released its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.01. Compugen had a negative return on equity of 47.40% and a negative net margin of 4,425.00%.
CGEN has been the topic of a number of research reports. FBR & Co set a $14.00 price objective on Compugen and gave the stock a “buy” rating in a report on Friday, May 19th. Zacks Investment Research downgraded Compugen from a “hold” rating to a “sell” rating in a report on Monday, May 22nd.
Several institutional investors have recently added to or reduced their stakes in CGEN. Renaissance Technologies LLC raised its stake in Compugen by 15.6% in the fourth quarter. Renaissance Technologies LLC now owns 534,900 shares of the biotechnology company’s stock worth $2,728,000 after buying an additional 72,075 shares during the period. Norges Bank bought a new stake in Compugen during the fourth quarter worth about $658,000. Vident Investment Advisory LLC raised its stake in Compugen by 22.2% in the fourth quarter. Vident Investment Advisory LLC now owns 125,514 shares of the biotechnology company’s stock worth $640,000 after buying an additional 22,820 shares during the period. Benjamin F. Edwards & Company Inc. raised its stake in Compugen by 5.7% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 66,300 shares of the biotechnology company’s stock worth $285,000 after buying an additional 3,600 shares during the period. Finally, Morgan Stanley raised its stake in Compugen by 9.4% in the first quarter. Morgan Stanley now owns 813,200 shares of the biotechnology company’s stock worth $3,497,000 after buying an additional 69,754 shares during the period. Institutional investors own 19.40% of the company’s stock.
Compugen (NASDAQ:CGEN) traded down 1.30% during trading on Thursday, reaching $3.80. The company’s stock had a trading volume of 4,551 shares. The company’s market capitalization is $194.30 million. Compugen has a 1-year low of $3.50 and a 1-year high of $7.57. The company’s 50-day moving average is $4.27 and its 200-day moving average is $4.51.
ILLEGAL ACTIVITY WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/06/210000-00-in-sales-expected-for-compugen-ltd-cgen-this-quarter.html.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.